Multiple sclerosis, an autoimmune demyelinating disease of the central nervous system, may benefit from the anti-inflammatory and neuroprotective properties of GLP-1RAs.137 Clinical observations indicate a reduced risk of multiple sclerosis relapse among T2DM patients treated with GLP-1RAs, potentially attributable to metabolic improvements and anti-inflammatory effects.138 Experimental autoimmune encephalomyelitis models have demonstrated that liraglutide attenuates central nervous system inflammation and demyelination.139 Additionally, GLP-1RAs have been shown to enhance motor function and prolong survival in amyotrophic lateral sclerosis models, reduce neuronal degeneration, improve behavioral outcomes in Huntingtons disease models, and confer neuroprotection following traumatic brain injury and stroke by mitigating inflammation, reducing cerebral edema, and promoting neurological recovery.129 GLP-1RAs and Mental Health Worldwide, approximately 35 million individuals suffer from substance use disorders, with an estimated 280 million affected by alcohol use disorder (AUD).140 Tobacco use is prevalent in approximately one-quarter of the global adult population.141 AUD is linked to elevated mortality rates due to medical complications, injuries,142 and suicide.143 AUDs ramifications extend beyond the afflicted individual, impacting family members144 and society at large

Furthermore, this financial obstacle prevents faster uptake despite recognized clinical benefits, predominantly in patient segments with low to intermediate incomes
For many people, Freya Meds offers an accessible entry point to therapies that were previously out of reach financially or logistically
A total of 1000 bootstrap replicates were assessed and the 95% confidence intervals for each parameter were calculated using the 2.5th and 97.5th percentile values from the distribution of bootstrap parameter values
Acetyl-L-carnitine is naturally present in the body in the brain, liver, and kidney
The cortisol elevation is mediated through stimulation of hypothalamic corticotropin-releasing hormone (CRH) release, which in turn activates the pituitary-adrenal axis